Antibody COVID-19NAT-COV-SURVNCT04459312
National Covid-19 Surveillance Physicians
An observational study of Antibody COVID-19, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
Trial summary
The investigators will analyze the presence of antibodies against SARS-COV2 in physicians working in emergency and intensive care medicine and in those who treat Covid 19 patients. Read more about this study
- Who is it for?
- Ages 18 to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Antibody COVID-19
- What is being tested?
- Antibody test (SARS-CoV2)
- How many people
- 600 participants
- Where
- 1 siteGermany
- Study dates
- 1 Jun 2020to 30 Sep 2020
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: All physicians working in german hospitals in emergency or intensive care medicine
Who may be able to join
- Qualified as physician
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
Germany1 site, 1 recruiting
- Recruiting
University Hospital Duesseldorf, Dept. of Anesthesiology
Düsseldorf, 40225
Detlef Kindgen-Milles, Prof., 004902118107047, kindgen-milles@med.uni-duesseldorf.de
About this study
Official title: National Covid-Surveillance Physicians
The investigators will analyze the presence of antibodies against SARS-COV2 in physicians working in emergency and intensive care medicine and in those who treat Covid 19 patients.
- Conditions
- Antibody COVID-19
- Being tested
- Antibody test (SARS-CoV2)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Antibody test (SARS-CoV2)Diagnostic test
Antibody test
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of antibodies against SARS-COV2
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2020
- Study start1 Jun 2020
- Primary completion10 Jul 2020 (estimated)
- Study completion30 Sep 2020 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Antibody COVID-19Studies of the same condition, open and under way.
- More trials run by Heinrich-Heine University, DuesseldorfThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Heinrich-Heine University, Duesseldorf
- Sponsor type
- University, hospital or other
- Collaborators
- Dr. Wetzchewald
- Responsible party
- Principal investigator, Klinik für Anästhesiologie, Heinrich-Heine University, Duesseldorf
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04459312
- Sponsor's protocol ID
- 2020_2
- Acronym
- NAT-COV-SURV
- Status last verified
- Jul 2020
- First submitted
- 3 Jul 2020
- Last updated
- 8 Jul 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- National Covid-Surveillance Physicians
- ClinicalTrials.gov ID
- NCT04459312
- Acronym / sponsor ID
- NAT-COV-SURV / 2020_2
- Conditions
- Antibody COVID-19
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Heinrich-Heine University, DuesseldorfUniversity, hospital or other
- Collaborators
- Dr. Wetzchewald
- Study start
- 1 Jun 2020 (actual)
- Primary completion
- 10 Jul 2020 (estimated)
- Study completion
- 30 Sep 2020 (estimated)
- First posted
- 7 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The investigators will analyze the presence of antibodies against SARS-COV2 in physicians working in emergency and intensive care medicine and in those who treat Covid 19 patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- All physicians working in german hospitals in emergency or intensive care medicine
Key inclusion criteria (1 listed)
- Qualified as physician
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Antibody test (SARS-CoV2)Antibody test | Diagnostic test | – |
Primary outcome
Presence of antibodies against SARS-COV2
Time frame: 3 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2020.
- Individual participant dataSharing planned: No
Related trials for Antibody COVID-19
Active, not recruitingObservational study
COVID-19 Immunity and Changes Over Time
COVID-19
RecruitingPhase 2
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
Post-COVID / Long-COVID
Active, not recruitingObservational study
A Longitudinal Study of COVID-19 Sequelae and Immunity
COVID-19
Active, not recruitingObservational study
COVID-19 Antibody Responses In Cystic Fibrosis
Covid19, Cystic Fibrosis
Not yet recruitingPhase 2
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Post-acute Infectious Syndrome (PAIS), Post-COVID 19 Condition (PCC or Long COVID)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
University Hospital Duesseldorf, Dept. of Anesthesiology
Düsseldorf, Germany
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Antibody COVID-19, run by Heinrich-Heine University, Duesseldorf at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of antibodies against SARS-COV2 (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2020.